October 30, 2024 10:39 AM EDTUpdated 01:32 PM
R&D

GSK cuts 24-va­lent pneu­mo­coc­cal pro­gram for adults due to com­pe­ti­tion

Nicole DeFeudis

Editor

GSK is set­ting aside a mid-stage 24-va­lent pneu­mo­coc­cal vac­cine pro­gram for adults to in­stead fo­cus on a pre­clin­i­cal op­tion that cov­ers 30-plus va­lents, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times